Tag: Show

  • Infant Formula Makers Were Required to Tell the FDA When Babies Died — Records Show They Never Did

    Infant Formula Makers Were Required to Tell the FDA When Babies Died — Records Show They Never Did

    When makers of infant formula learn that babies have become seriously ill or died after using their products, federal regulations require them to notify the FDA. But in a major investigative finding published July 2, 2026, KFF Health News revealed that the FDA has no record of a single such notification from any formula manufacturer going back more than 26 years.

    That gap in the federal safety record is not because premature infants haven’t died. According to a KFF Health News analysis of federal data, approximately 2,300 newborns died from necrotizing enterocolitis (NEC) in the United States between 2017 and 2023 — roughly one per day. A wave of more than 1,700 lawsuits has alleged that formula made by Abbott (Similac) and Mead Johnson (Enfamil) caused or contributed to these deaths by triggering NEC in premature infants, and that manufacturers knew about the elevated risk without adequately warning parents or physicians.


    Why This Matters

    Federal regulations give infant formula manufacturers substantial discretion in deciding whether and when to notify the FDA that a product may have contributed to a serious adverse event. According to KFF Health News’s investigation, that discretion has translated to zero notifications — even as hundreds of lawsuits proceeded through the courts and testimony from company executives confirmed that internal records of adverse events existed and were investigated internally.

    The practical consequence is significant: parents harmed by formula have been fighting Abbott and Mead Johnson in court, with no government notification system creating an independent safety record. Families who lose a premature infant to NEC are not informed that other families have reported the same outcome to the manufacturer. And the FDA — which does not pre-approve infant formula before it reaches the market — has had no formal mechanism to detect a pattern of harm tied to specific products.


    What We Know So Far

    From KFF Health News’s FOIA investigation published July 2, 2026, and court records cited in the report:

    • Under the Freedom of Information Act, KFF Health News asked the FDA for all notifications from formula manufacturers since January 1, 2020. The agency’s Human Foods Program responded: “did not receive any.”
    • KFF Health News extended the request to January 1, 2000. The FDA responded: “After a diligent search of our files, we did not locate any responsive records.”
    • John Wallingford, a paid expert witness for Abbott, testified in Missouri court in October 2024 that “Abbott had never reported a single death under any regulation for preterm infant formula.”
    • Courtney Colombo, who identified herself in a March 2024 deposition as Abbott’s director of postmarketing medical safety and surveillance, testified she knew of no instance in which Abbott had reported to any regulatory authority anywhere in the world that one of its preterm infant formulas was possibly related to a NEC death.
    • An Abbott internal document from 2010, displayed in deposition video clips obtained by KFF Health News, stated that NEC “is the most severe GI complication of prematurity and the use of bovine milk-based fortifiers and formulas are believed to be the primary risk factor.”
    • A Mead Johnson marketing slide deck from 2020 — later used in trial — outlined a plan for “Branding NICU Babies,” a strategy to capture preterm infant feeding contracts through hospital relationships.
    • As of late January 2026, approximately 1,760 NEC lawsuits were pending against Abbott alone.
    • About 2,300 newborns died of NEC in the U.S. from 2017 through 2023, the equivalent of nearly one per day. The database does not attribute causation.

    Where the System Fails Families

    The regulatory framework governing infant formula reporting gives manufacturers the authority to determine whether adverse events — including deaths — meet the threshold requiring FDA notification. Unlike pharmaceutical drugs, which are subject to rigorous post-market surveillance and mandatory serious adverse event reporting with specific timelines, infant formula operates under a framework in which reporting is largely at the manufacturer’s discretion.

    The FDA does not approve infant formula products before they reach market. It does not license formula labeling for safety claims. And, according to the KFF Health News investigation, its Human Foods Program received zero death notifications from formula makers across a 26-year window — even as internal company documents confirmed the companies were tracking NEC-related complaints internally.

    This creates a structural gap: a manufacturer can investigate an adverse event internally, close the file internally, and the FDA may never receive a notification that allows it to identify a pattern of harm.


    What the Companies and Agencies Say

    Abbott spokesperson Scott Stoffel stated in November that “Abbott complies with all applicable FDA regulations on adverse event reporting, including by keeping detailed records of every single complaint/adverse event report Abbott receives and investigating NEC complaints.”

    The FDA stated in a 2024 joint statement with the CDC and NIH that there is “no conclusive evidence that preterm infant formula causes NEC.” Abbott’s chief executive has publicly said that claims linking preterm formula to NEC are “without merit or scientific support.”

    However, courts have repeatedly found in favor of families suing Abbott and Mead Johnson. A Chicago jury awarded $53 million to four families in April 2026, and a separate Chicago verdict in the same month awarded an additional $70 million. A Missouri appeals court upheld a $495 million verdict against Abbott. As of June 2026, approximately 798 federal NEC cases remain pending in multidistrict litigation in the Northern District of Illinois, with hundreds more in state courts.


    What the Evidence Shows — and What It Does Not

    The scientific debate over whether bovine (cow’s milk-based) formula causes NEC in premature infants versus the absence of human milk increasing NEC risk is ongoing and genuinely contested. The FDA, CDC, and NIH have stated there is no conclusive causal evidence. The American Academy of Pediatrics recommends human milk — including pasteurized donor milk — for premature infants when the mother’s own milk is not available.

    What is not contested is the reporting record: the FDA received no death notifications from formula manufacturers going back to 2000, and Abbott’s own expert witness confirmed the company made no such reports.

    MedicalDaily Evidence Check

    • Investigation type: FOIA requests + court record analysis (KFF Health News, published July 2, 2026)
    • What it found: Zero FDA death notifications from formula manufacturers from January 2000 through the present; Abbott’s expert witness confirmed Abbott never made a single death report under any regulation for preterm formula
    • What it did not prove: That the formula directly caused the deaths — this remains contested between companies and plaintiffs
    • Regulatory context: FDA does not pre-approve infant formula; adverse event reporting for formula is largely at manufacturers’ discretion
    • What readers should know: The regulatory gap in formula death reporting is confirmed by FOIA records; families of premature infants have been fighting manufacturers in court without a government notification system creating an independent safety record

    Who Is Most Affected?

    This issue affects:

    • Parents of premature infants currently in NICUs who are receiving cow’s milk-based formula or fortifiers
    • Families who have experienced a premature infant death from NEC and may not know there is a reporting gap at the regulatory level
    • NICU clinicians and hospitals whose informed consent discussions about formula feeding may not have reflected the manufacturer’s internal awareness of NEC-related adverse events
    • Policymakers and advocates working on infant formula regulation reform

    Symptoms of NEC in Premature Infants

    Necrotizing enterocolitis typically develops in premature infants two to four weeks after birth, often around the time feedings begin. Warning signs that require immediate evaluation by the neonatal team include:

    • Sudden abdominal swelling or rigidity
    • Feeding intolerance after previously tolerating feeds
    • Bloody stool
    • Temperature instability
    • Lethargy or decreased responsiveness
    • Skin discoloration over the abdomen

    If your premature infant is in the NICU, ask the neonatal team specifically about NEC risk and what the protocol is for early detection.


    What You Can Do Now

    • If your premature infant is currently in a NICU, ask the neonatologist whether your baby is receiving human donor milk or cow’s milk-based formula, and what the facility’s protocol is for NEC monitoring.
    • Ask about your baby’s NEC risk based on gestational age and birth weight — infants born before 32 weeks and those under 1,500 grams face the highest risk.
    • Inquire about human milk availability at the facility. The American Academy of Pediatrics recommends human milk — including pasteurized donor milk — as the preferred nutrition for very premature infants.
    • If your premature infant previously suffered NEC while receiving cow’s milk-based formula, you may wish to consult a legal professional about your options. As of June 2026, active multidistrict litigation is proceeding in the Northern District of Illinois.
    • Report adverse events through the FDA’s MedWatch program if you believe a formula product contributed to a serious adverse event in your infant.

    Cost and Access: What Patients Should Know

    Human donor milk is more expensive than cow’s milk-based formula, and insurance coverage varies. NICU families should ask the billing department and the neonatology team about donor milk access and coverage. Many NICUs absorb donor milk costs for the highest-risk infants.

    For families who believe their infant was harmed by formula, legal consultations are typically offered at no upfront cost by firms handling NEC formula litigation. The Pancreatic Cancer Action Network NICHD page on NEC and infant feeding provides a recent scientific overview of the evidence.


    What Happens Next

    The KFF Health News investigation is expected to prompt renewed regulatory scrutiny of infant formula adverse event reporting requirements. The ongoing multidistrict litigation will produce additional bellwether trials in 2026 that may increase pressure on Abbott and Mead Johnson to consider broader settlements.

    Congress has shown some interest in strengthening formula safety oversight following the 2022 Abbott infant formula shortage and contamination recall. Whether the KFF Health News reporting prompts legislative action on adverse event reporting requirements remains to be seen.


    The Bottom Line

    The FDA received zero death notifications from infant formula manufacturers going back to the year 2000, according to FOIA records obtained by KFF Health News — confirmed by Abbott’s own expert witness, who testified the company never made a single such report for preterm formula. Approximately 2,300 premature infants died of NEC in the U.S. between 2017 and 2023. The combination of those two facts is not proof of causation — but it is a documented regulatory gap that left families fighting for accountability in court with no independent government safety record to draw on.

    Source link

  • New Cancer Treatments Show Promise Against Some of the Deadliest Tumors, Researchers Report

    New Cancer Treatments Show Promise Against Some of the Deadliest Tumors, Researchers Report

    Recent advances in cancer research are offering new hope for patients with some of the most difficult-to-treat forms of the disease, with scientists reporting encouraging results from experimental therapies targeting pancreatic, lung, and head and neck cancers.

    The developments were highlighted during presentations at major oncology meetings and reported by The Guardian on June 1, as researchers unveiled data suggesting that several next-generation treatments may improve outcomes for patients who have exhausted standard options. The Guardian report

    One of the most closely watched breakthroughs involves daraxonrasib, an experimental pill designed to target RAS-driven cancers. According to reports from oncology researchers cited by The Guardian, the drug nearly doubled median survival among patients with advanced pancreatic cancer in a recent clinical trial. Pancreatic cancer remains one of the deadliest malignancies worldwide, with survival rates lagging behind many other major cancer types. (The Guardian)

    Researchers also reported progress in head and neck cancer treatment using amivantamab, a targeted therapy that has demonstrated tumor reduction in patients whose disease continued to progress despite chemotherapy and immunotherapy. Trial findings showed that a significant number of participants experienced measurable responses to the treatment, raising hopes for a patient population with limited therapeutic options. (The Guardian)

    Separately, investigators presented early clinical trial data for GRWD5769, an experimental immunotherapy-enhancing drug developed to help the immune system recognize cancer cells more effectively. In a Phase 1 study involving patients with advanced cancers, tumors shrank in multiple participants, including those with lung, bowel, bladder, liver, cervical, and head and neck cancers. Researchers said the therapy works by disrupting a mechanism that allows cancer cells to evade immune detection. (The Guardian)

    The findings come amid growing concern over the global cancer burden. According to figures cited by The Guardian, cancer causes nearly 10 million deaths each year worldwide, while approximately 100,000 new diagnoses are made daily. Experts have also raised concerns about increasing cancer incidence among younger adults, a trend that continues to be investigated. (The Guardian)

    Despite the positive developments, researchers cautioned that many of the treatments remain experimental and require additional testing before broader adoption. Larger clinical trials will be needed to confirm long-term benefits, assess safety, and determine which patients are most likely to respond.

    Still, oncology experts say the recent results underscore a broader shift toward precision medicine, where therapies are increasingly designed to target specific genetic and biological characteristics of tumors rather than relying solely on conventional treatment approaches. (The Guardian)

    Source: The Guardian reported on June 1 that emerging cancer therapies, including daraxonrasib for pancreatic cancer, amivantamab for head and neck cancer, and the investigational drug GRWD5769, are showing promising results in clinical studies, fueling optimism among cancer researchers despite ongoing challenges in treatment and diagnosis. (The Guardian)

    Related Links:

    Source link

  • 4 Quick Ways to Nurture & Show Love, Anytime

    4 Quick Ways to Nurture & Show Love, Anytime

    Here are some easy ways to show love with simple mindful actions that foster genuine connection and appreciation.

    You might love the month of love, or you might not be into the whole Valentine’s Day thing. With $18 billion spent every February on flowers, chocolates, gifts, and restaurants in the United States every year, it’s safe to say that we have certain cultural ideas about how to show love.

    So why not use the occasion to really celebrate love?

    Here are a few ways to show love during this heart-stamped month, or any time of year—and none of them cost a penny.

    Listen—really listen. That means giving them your openminded, genuinely interested attention, according to mindful communication experts Hope Martin and David Rome. Take the time to fully absorb what they’re saying. Body language, word choice, tone of voice—you’ll be amazed at what you may have been missing.

    Offer your full presence when you’re together. Don’t look at your phone. Show love by showing up fully, without distractions. Resist the usual complaining about work. Slipping onto autopilot—a you-do-this/ I-do-that dynamic—is no fun and can erode any relationship, says Marsha Lucas, a neuropsychologist and the author of Rewire Your Brain for Love.

    Value the little things someone does for you—and do some in return. Relationship coach Josh Wise suggests that couples take gratitude a step further: discuss the kindnesses you receive and how that makes you feel. In this way, you get to multiply the effect of thoughtful actions—first by experiencing it, then by sharing it, and then again by noticing how your recognition lifts the other person up.

    Empathy. It’s a necessary ingredient for healthier relationships of all kinds. According to psychologist Ronald Siegel in The Mindfulness Solution, “When we can actually be with someone and empathize with his or her experience, even when it’s painful, the relationship deepens.”


    This article also appeared in the February 2014 issue of Mindful magazine.



    Source link

  • Subtle Pregnancy Symptoms Week 1 That Show Up Before a Missed Period

    Subtle Pregnancy Symptoms Week 1 That Show Up Before a Missed Period

    Early pregnancy signs can appear before a missed period, and many people notice subtle body changes in the days after conception. These symptoms can be confusing because they often overlap with premenstrual syndrome (PMS), making it hard to tell what is happening without a test.

    Can You Feel Pregnancy Symptoms Before a Missed Period?

    Some individuals report early pregnancy signs as soon as one to two weeks after conception, even before the expected period. Hormonal changes, particularly rising levels of human chorionic gonadotropin (hCG) and progesterone, can trigger symptoms such as fatigue, breast tenderness, and mood shifts during this time.​

    These early changes are not the same for everyone, and some may feel no noticeable symptoms at all before a missed period. Because these sensations can mimic PMS, pregnancy cannot be confirmed based on symptoms alone and still requires a reliable test.​

    What Are The Earliest Pregnancy Symptoms Before a Missed Period?

    Many of the earliest pregnancy symptoms week 1 are subtle and easy to overlook. However, patterns of small changes in how the body feels can suggest that implantation and early pregnancy are underway.​

    The presence, absence, or intensity of these early pregnancy signs does not reliably predict how the pregnancy will progress. Each pregnancy can feel different, even for the same person across different pregnancies.​

    Sore or Tender Breasts

    Breast changes are among the most commonly reported early pregnancy signs before a missed period. Hormonal shifts can cause soreness, swelling, a feeling of fullness, or increased sensitivity of the nipples, sometimes beginning within days after conception.​

    This symptom can resemble premenstrual breast tenderness, but in early pregnancy it may feel more intense or last longer than usual. Some also notice darker areolas or more visible veins on the breasts as blood flow increases.​

    Mild Cramping and Implantation Pain

    Light, period-like cramping can occur when the fertilized egg implants into the uterine lining, usually about 6 to 12 days after ovulation. These cramps are often described as mild, intermittent, or localized rather than strong and widespread.​

    Implantation-related cramping typically does not involve severe pain and does not last as long as a usual menstrual cramp episode. Strong or one-sided pain, especially with heavy bleeding, is not typical and should be checked by a healthcare professional.​

    Light Spotting or Implantation Bleeding

    Implantation bleeding is another possible early pregnancy sign before a missed period. It usually appears as very light pink or brown spotting on underwear or toilet tissue, and it often lasts from a few hours to a couple of days, according to Mayo Clinic.​

    This spotting is generally lighter than a normal period and does not require the same level of sanitary protection. Heavy bleeding, bright red flow, or bleeding with clots and significant pain should be discussed with a clinician as soon as possible.​

    Nausea, With or Without Vomiting

    Nausea does not always wait until later in the first trimester; it can appear even before a missed period in some pregnancies. This queasiness is sometimes called morning sickness, but it may occur at any time of day or be triggered by motion, an empty stomach, or certain foods.​

    Vomiting does not need to be present for nausea to be related to pregnancy. If nausea is severe, persistent, or prevents adequate food and fluid intake, medical guidance is important.​

    Bloating and Digestive Changes

    Hormonal shifts, especially higher progesterone, can slow digestion and contribute to bloating, gas, or constipation very early in pregnancy. This can make the abdomen feel fuller or tighter than usual even before the uterus has enlarged significantly.​

    Because PMS can cause similar bloating, this symptom alone is not a reliable indicator of pregnancy. When bloating appears along with other early pregnancy signs, it may add to the overall pattern of clues.​

    Mood Swings and Emotional Changes

    Mood swings are common both in PMS and in early pregnancy, and they can include irritability, sadness, anxiety, or sudden changes in emotions. Fluctuating progesterone and estrogen levels, along with stress about trying to conceive, may contribute to these shifts, as per Cleveland Clinic.​

    Because mood symptoms are so nonspecific, they are most meaningful when combined with other early pregnancy signs. If mood changes are persistent or severe, mental health support can be beneficial regardless of pregnancy status.​

    Raised Basal Body Temperature

    For those who track fertility, a consistently elevated basal body temperature (BBT) is one of the more technical early pregnancy signs. After ovulation, BBT normally rises slightly; if it remains higher than usual for more than about two weeks, early pregnancy may be a possibility.​

    Tracking BBT requires daily measurements under similar conditions and is often used alongside ovulation charting. On its own, an isolated high reading is less meaningful than a sustained pattern across multiple days.​

    What Are Pregnancy Symptoms in Week 1?

    The phrase “pregnancy symptoms week 1” can be confusing, because medically week 1 is counted from the first day of the last menstrual period, when conception has not yet occurred.

    During this very early phase, common experiences may include mild cramping, breast tenderness, fatigue, slight bloating, and subtle nausea or food aversions. Some people feel almost no changes at all, while others are very sensitive to hormonal shifts.​

    How Do Early Pregnancy Symptoms Differ From PMS?

    Early pregnancy symptoms and PMS share many features, including breast tenderness, mood swings, bloating, and mild cramps. The main differences are often in timing, duration, and progression rather than in the specific symptoms themselves.​

    In early pregnancy, symptoms may start slightly earlier than usual, feel more intense, or continue beyond the expected start of the period instead of resolving. Despite these patterns, only a pregnancy test can reliably distinguish between PMS and pregnancy.​

    Understanding Early Pregnancy Signs Before a Missed Period

    Recognizing early pregnancy signs and common pregnancy symptoms week 1 can help someone tune into their body and make informed decisions about testing and medical care.

    While symptoms such as breast tenderness, mild cramping, fatigue, nausea, and light spotting can appear before a missed period, they are not definitive proof of pregnancy on their own.​

    An objective approach combines awareness of these early clues with timely pregnancy testing and appropriate medical follow-up when needed. Paying attention to patterns, tracking cycles, and seeking professional advice concerning symptoms can provide clarity during the uncertain days before a missed period.​

    Frequently Asked Questions

    1. Can early pregnancy signs come and go from day to day?

    Yes, early pregnancy signs can fluctuate, and it is common for symptoms to appear one day and feel milder or absent the next. Hormone levels rise gradually, so fatigue, nausea, breast tenderness, or bloating can vary in intensity instead of staying constant.​

    2. Do all people experience pregnancy symptoms in week 1?

    No, many people feel no noticeable pregnancy symptoms in week 1, even if conception has occurred. The body may still be in the very early stages of implantation and hormonal change, so symptoms can be minimal or completely absent at first.​

    3. Can stress or anxiety cause signs that feel like early pregnancy symptoms?

    Stress and anxiety can create physical sensations that resemble early pregnancy signs, such as fatigue, sleep changes, stomach upset, or increased awareness of bodily sensations. Because of this overlap, symptoms alone are not a reliable way to confirm pregnancy without testing.​

    4. Is it possible to have early pregnancy signs but still get a negative test?

    Yes, it is possible to notice early pregnancy signs and still see a negative result if testing is done too early, before hCG levels are high enough to detect. Waiting a few days and retesting, or consulting a healthcare professional, can provide clearer answers.​



    Source link